Logo image of INSM

INSMED INC (INSM) Stock Fundamental Analysis

USA - NASDAQ:INSM - US4576693075 - Common Stock

145.03 USD
+0.27 (+0.19%)
Last: 9/22/2025, 8:34:07 PM
144.91 USD
-0.12 (-0.08%)
After Hours: 9/22/2025, 8:34:07 PM
Fundamental Rating

4

Overall INSM gets a fundamental rating of 4 out of 10. We evaluated INSM against 538 industry peers in the Biotechnology industry. The financial health of INSM is average, but there are quite some concerns on its profitability. INSM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

In the past year INSM has reported negative net income.
INSM had a negative operating cash flow in the past year.
INSM had negative earnings in each of the past 5 years.
INSM had a negative operating cash flow in each of the past 5 years.
INSM Yearly Net Income VS EBIT VS OCF VS FCFINSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

With a Return On Assets value of -41.71%, INSM perfoms like the industry average, outperforming 57.43% of the companies in the same industry.
INSM has a Return On Equity (-82.76%) which is in line with its industry peers.
Industry RankSector Rank
ROA -41.71%
ROE -82.76%
ROIC N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INSM Yearly ROA, ROE, ROICINSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

INSM's Gross Margin of 75.72% is amongst the best of the industry. INSM outperforms 83.09% of its industry peers.
INSM's Gross Margin has been stable in the last couple of years.
INSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
INSM Yearly Profit, Operating, Gross MarginsINSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

5

2. Health

2.1 Basic Checks

INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INSM has more shares outstanding
Compared to 5 years ago, INSM has more shares outstanding
The debt/assets ratio for INSM has been reduced compared to a year ago.
INSM Yearly Shares OutstandingINSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
INSM Yearly Total Debt VS Total AssetsINSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

INSM has an Altman-Z score of 11.92. This indicates that INSM is financially healthy and has little risk of bankruptcy at the moment.
INSM has a better Altman-Z score (11.92) than 87.55% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that INSM is not too dependend on debt financing.
The Debt to Equity ratio of INSM (0.45) is worse than 71.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z 11.92
ROIC/WACCN/A
WACC9.75%
INSM Yearly LT Debt VS Equity VS FCFINSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

INSM has a Current Ratio of 6.68. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.68, INSM is doing good in the industry, outperforming 67.10% of the companies in the same industry.
A Quick Ratio of 6.33 indicates that INSM has no problem at all paying its short term obligations.
INSM's Quick ratio of 6.33 is fine compared to the rest of the industry. INSM outperforms 65.99% of its industry peers.
Industry RankSector Rank
Current Ratio 6.68
Quick Ratio 6.33
INSM Yearly Current Assets VS Current LiabilitesINSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

7

3. Growth

3.1 Past

INSM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.94%.
INSM shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.15%.
The Revenue has been growing by 21.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.37%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%18.9%

3.2 Future

INSM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.02% yearly.
Based on estimates for the next years, INSM will show a very strong growth in Revenue. The Revenue will grow by 64.71% on average per year.
EPS Next Y-0.1%
EPS Next 2Y16.82%
EPS Next 3Y22.85%
EPS Next 5Y27.02%
Revenue Next Year29.87%
Revenue Next 2Y71.12%
Revenue Next 3Y76.22%
Revenue Next 5Y64.71%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INSM Yearly Revenue VS EstimatesINSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B 8B
INSM Yearly EPS VS EstimatesINSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
Also next year INSM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INSM Price Earnings VS Forward Price EarningsINSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INSM Per share dataINSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

INSM's earnings are expected to grow with 22.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.82%
EPS Next 3Y22.85%

0

5. Dividend

5.1 Amount

No dividends for INSM!.
Industry RankSector Rank
Dividend Yield N/A

INSMED INC

NASDAQ:INSM (9/22/2025, 8:34:07 PM)

After market: 144.91 -0.12 (-0.08%)

145.03

+0.27 (+0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-29 2025-10-29
Inst Owners109.14%
Inst Owner Change0.04%
Ins Owners0.82%
Ins Owner Change-11.14%
Market Cap30.65B
Analysts85.38
Price Target156.83 (8.14%)
Short Float %5.06%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.66%
Min EPS beat(2)-28.87%
Max EPS beat(2)-4.46%
EPS beat(4)0
Avg EPS beat(4)-11.73%
Min EPS beat(4)-28.87%
Max EPS beat(4)-2.38%
EPS beat(8)2
Avg EPS beat(8)-10.89%
EPS beat(12)2
Avg EPS beat(12)-14.95%
EPS beat(16)4
Avg EPS beat(16)-10.08%
Revenue beat(2)1
Avg Revenue beat(2)0.13%
Min Revenue beat(2)-1.17%
Max Revenue beat(2)1.43%
Revenue beat(4)1
Avg Revenue beat(4)-0.42%
Min Revenue beat(4)-1.53%
Max Revenue beat(4)1.43%
Revenue beat(8)2
Avg Revenue beat(8)-1.08%
Revenue beat(12)3
Avg Revenue beat(12)-0.69%
Revenue beat(16)5
Avg Revenue beat(16)-0.1%
PT rev (1m)33.03%
PT rev (3m)37.64%
EPS NQ rev (1m)-1.54%
EPS NQ rev (3m)-0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.28%
Revenue NQ rev (1m)-0.78%
Revenue NQ rev (3m)0.2%
Revenue NY rev (1m)-0.39%
Revenue NY rev (3m)3.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 77
P/FCF N/A
P/OCF N/A
P/B 24.53
P/tB 28.99
EV/EBITDA N/A
EPS(TTM)-5.71
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-4.11
FCFYN/A
OCF(TTM)-4
OCFYN/A
SpS1.88
BVpS5.91
TBVpS5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.71%
ROE -82.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.72%
FCFM N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 159.38%
Cap/Sales 6.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.68
Quick Ratio 6.33
Altman-Z 11.92
F-Score4
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)113.37%
Cap/Depr(5y)86.53%
Cap/Sales(3y)4.8%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.37%
EPS Next Y-0.1%
EPS Next 2Y16.82%
EPS Next 3Y22.85%
EPS Next 5Y27.02%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%18.9%
Revenue Next Year29.87%
Revenue Next 2Y71.12%
Revenue Next 3Y76.22%
Revenue Next 5Y64.71%
EBIT growth 1Y-44.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.82%
EBIT Next 3Y23.47%
EBIT Next 5YN/A
FCF growth 1Y-82.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.77%
OCF growth 3YN/A
OCF growth 5YN/A